Editas Medicine (EDIT) Financials

Editas Medicine’s Q1 2026 results show a company still in heavy cash-burn mode, but with a very large cash cushion after a major step-down in assets over the past year. Revenue dropped to zero in the quarter, operating losses remained substantial, and cash on hand declined from prior quarters. At the same time, the balance sheet still shows more than $123 million in cash and equivalents, which gives the company runway—but not unlimited flexibility—while it advances its pipeline.

• Cash balance remains meaningful: Editas ended Q1 2026 with $123.6 million in cash and equivalents, which is enough to support near-term operations.
• Investing cash flow was slightly positive: The company generated $64,000 of net cash from investing activities in Q1 2026, helped by asset sales.
• Other income helped offset losses: Interest and investment income plus other items contributed to a small amount of non-operating support in the quarter.
• Debt appears manageable in the near term: Short-term debt was $7.5 million at quarter-end, while long-term debt was $47.2 million.
• Spending remains focused on R&D: Research and development expense was $14.8 million, showing the company is still investing in its pipeline.
• Shares outstanding were relatively stable sequentially: Basic and diluted weighted average shares were both about 97.9 million in Q1 2026.
• No revenue in Q1 2026: Total revenue was $0, compared with $29.4 million in Q4 2025, highlighting the uneven and limited nature of commercial activity.
• Operating losses remain large: The company reported an operating loss of $25.0 million and a net loss of $24.9 million for the quarter.
• Operating cash burn continued: Net cash from operating activities was negative $23.1 million in Q1 2026.
• Cash declined sharply from prior quarter levels: Cash and equivalents fell from $165.6 million in Q3 2025 to $123.6 million in Q1 2026.

Longer-term trend: Editas has not shown sustained profitability over the last four years. Revenue has been inconsistent, with occasional collaboration or milestone-related quarters offset by multiple periods of no revenue at all. Meanwhile, operating expenses have remained high, and quarterly losses have often ranged from roughly $20 million to more than $70 million depending on restructuring charges and other items.

The good news is that the company has maintained a sizable liquidity position through asset sales, investment maturities, and periodic equity issuance. The concern is that the core business still does not generate enough revenue to cover operating costs, so investors should continue to watch cash burn, pipeline progress, and any future financing needs very closely.